$ICU News

SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury

SeaStar Medical's Selective Cytopheretic Device Receives Dedicated International Classification of Diseases Codes From U.S. CMS, Facilitating Future Billing Procedures

SeaStar Medical to Present at Upcoming Investor Summit Conference

ICU: YoY Revenue Increases 69%

Maxim Group Maintains Buy on SeaStar Medical Holding, Raises Price Target to $8

SeaStar Medical Holding Corporation Q2 2026 Earnings Call Summary

SeaStar Medical Holding Corp (ICU) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

SeaStar Medical (ICU) Q1 2026 Earnings Transcript

Full Transcript: SeaStar Medical Holding Q1 2026 Earnings Call

SeaStar Medical Beats Q1 Revenue Estimates, But EPS Miss Tempers Enthusiasm for ICU Stock

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

Full Transcript: SeaStar Medical Holding Q1 2026 Earnings Call

SeaStar Medical Holding Q1 EPS $(0.90) Misses $(0.82) Estimate, Sales $495.000K Beat $437.500K Estimate

SeaStar Medical to Report First Quarter Financial Results on May 13, 2026

ICU: Poster Presentations at AKI & CRRT 2026 Highlight SAVE Registry Data and SCD MOA

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical shares are trading higher after the company announced the presentation of new SAVE Registry data and investigator-led research on the mechanism of action of the Selective Cytopheretic Device therapy.

SeaStar Medical shares are trading higher after the company announced the presentation of new SAVE Registry data and investigator-led research on the mechanism of action of the Selective Cytopheretic Device therapy.

SeaStar Medical Announces Positive Data From QUELIMMUNE SAVE Registy, And Availability Of New Research On Selective Cytopheretic Device Therapy